DeepMed Research

Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

Phase 1

Completed

Conditions: HIV Infections
HIV Seronegativity
Lipodystrophy

First Posted Date: 2001-08-31

Last Posted Date: 2006-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 56

Registration Number: NCT00017758

Locations: 🇺🇸
Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸
Univ of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Washington Univ School of Medicine, St Louis, Missouri, United States

and more 7 locations

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-11-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 68

Registration Number: NCT00002239

Locations: 🇺🇸
UCLA Care Ctr, Los Angeles, California, United States
🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸
Pennsylvania Oncology and Hematology Associates, Philadelphia, Pennsylvania, United States

and more 16 locations

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Phase 3

Suspended

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Triangle Pharmaceuticals

Registration Number: NCT00002362

Locations: 🇺🇸
Northstar Med Clinic, Chicago, Illinois, United States
🇺🇸
Houston Clinical Research Network, Houston, Texas, United States
🇺🇸
Univ of Texas / Med School at Houston, Houston, Texas, United States

and more 7 locations

Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT00002220

Locations: 🇺🇸
Hawaii AIDS Clinical Trial Unit, Honolulu, Hawaii, United States
🇺🇸
LAC / USC Med Ctr / Infectious Diseases, Los Angeles, California, United States
🇺🇸
Med Ctr of Delaware, Wilmington, Delaware, United States

and more 8 locations

A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Northwestern University

Target Recruit Count: 100

Registration Number: NCT00002230

Locations: 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States

A Study of Efavirenz in Combination With Stavudine and Didanosine

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Dupont Merck

Target Recruit Count: 60

Registration Number: NCT00002225

Locations: 🇺🇸
Univ of Rochester Med Ctr, Rochester, New York, United States
🇺🇸
AIDS Research Alliance - Chicago, Chicago, Illinois, United States
🇺🇸
North Shore AIDS Hosp / Division of Infectious Disease, Manhassett, New York, United States

and more 2 locations

A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT00002448

Locations: 🇺🇸
Palo Alto Veterans Affairs Health Care System, Palo Alto, California, United States
🇺🇸
UCLA Care Ctr, Los Angeles, California, United States
🇺🇸
Robert Wood Johnson Med School/UMDNJ, New Brunswick, New Jersey, United States

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 103

Registration Number: NCT00000893

Locations: 🇺🇸
The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States
🇺🇸
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States
🇺🇸
Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States

and more 24 locations

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

Phase 4

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 40

Registration Number: NCT00004585

Locations: 🇺🇸
George Washington Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸
Tower Infectious Diseases / Med Associates Inc, Los Angeles, California, United States
🇺🇸
North Shore Univ Hosp, Manhasset, New York, United States

and more 2 locations

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

Not Applicable

Withdrawn

Conditions: HIV Infections
Hepatitis C

First Posted Date: 2001-08-31

Last Posted Date: 2015-03-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00023218

Locations: 🇺🇸
Univ of Hawaii, Honolulu, Hawaii, United States
🇺🇸
Beth Israel Med Ctr, New York, New York, United States
🇺🇸
Tripler Army Med Ctr, Tripler AMC, Hawaii, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy